What Ivomec F Treats: Main Uses and Benefits

---

The combined formulation of this veterinary medicine is commonly used to help with the treatment and control of certain internal parasitic infestations. This therapeutic combination is relevant for easing the symptomatic burden of gastrointestinal roundworms, lungworms, and adult liver flukes (Fasciola hepatica) simultaneously. By addressing the underlying parasitic stress, treatment assists with addressing symptoms related to systemic imbalance, such as chronic ill-thrift and impaired feed conversion, which may assist with maintaining functional stability and supports general well-being. The dual use is helpful in situations where symptoms are driven by both internal (nematodes and trematodes) and external (arthropod) factors.

Ivomec F is also applied across domains where additional symptomatic support is needed to manage external parasitic conditions. By addressing the cause of infestation, the treatment helps address severe skin irritation, pruritus, and hair loss, which may support general well-being during symptomatic phases and contribute to improved comfort. It is commonly integrated into strategic parasite control programs to manage mixed infestations.

“The treatment supports the patient during difficult episodes by contributing to sustained protection against the re-establishment of several important roundworm species.”

---

Quick Fact: Supportive Management of Parasite Symptoms

Eligibility Scope

Ivomec F is an approved veterinary medicine whose eligibility is defined by species and food safety regulations. Use is strictly allowed in cattle, including pregnant beef cows and breeding bulls, as stated in the regulatory label. Eligibility is not established for any other animal species, and the medicine is contraindicated for use in humans.

Contraindicated Populations

Regulatory documents formally prohibit the use of this product in several specific cattle populations due to food residue concerns. The medicine must not be used in female dairy cattle of breeding age because a withdrawal time in milk is not established. Similarly, use is prohibited in calves intended for veal processing or pre-ruminating calves, as the required withdrawal period has not been established for these groups.

Eligibility-Related Restrictions

Use is restricted in all treated cattle by a 21-day pre-slaughter withdrawal period.

Conditional use applies to cattle with migrating cattle grubs; treatment must be timed to avoid the severe adverse host reactions that can occur if the larvae are destroyed in vital areas.

Ivomec F contains Ivermectin and Clorsulon, but the documented human drug-drug interactions are primarily attributed to Ivermectin. Patients must inform their healthcare provider about all concurrent medications, supplements, and products.

Documented Interaction Categories

Interacting Product Category	Mechanism and Clinical Concern
Oral Anticoagulants (e.g., Warfarin)	Co-administration has been associated with rare postmarketing reports of increased International Normalized Ratio (INR), which may indicate an enhanced blood-thinning effect and increased risk of bleeding.
CYP3A4 Inhibitors	Ivermectin is primarily metabolized by the CYP3A4 enzyme in the liver. Concomitant use with inhibitors of this enzyme (e.g., certain antifungals, antivirals, or antibiotics) can lead to decreased Ivermectin metabolism and potentially elevated serum concentrations, increasing the risk of Ivermectin-related side effects.
P-glycoprotein (P-gp) Modulators	Ivermectin is a substrate and in-vitro inhibitor of the P-glycoprotein transporter. Drugs that also interact with P-gp may alter the absorption and disposition of Ivermectin or be affected by Ivermectin, though the clinical significance varies.

Clinical and Population Notes

• Immune-Compromised Patients: Individuals with conditions that affect the immune system (e.g., HIV) may have a reduced response to Ivermectin, which may necessitate additional monitoring or dosing strategies.
• Interaction Severity: The interaction with oral anticoagulants is considered clinically significant, requiring careful monitoring of clotting parameters to manage the potential for excessive anticoagulation.

How Ivomec F Works

Ivomec F utilizes a dual-action mechanism that simultaneously targets two fundamentally different biological vulnerabilities across distinct classes of parasites, resulting in a broad spectrum of antiparasitic mechanisms.

---

Invertebrate Neural Signal Blockade

This domain involves Ivermectin, which acts as a highly specific modulator of glutamate-gated chloride channels ( GluCl) found in the nerve and muscle cells of susceptible nematodes and arthropods. By inducing the continuous opening of these channels, the drug initiates a massive influx of chloride ions, which causes the parasite's nerve cells to enter a state of irreversible hyperpolarization. This molecular cascade effectively halts signal transmission, resulting in flaccid paralysis and subsequent organism death.

---

Fluke Metabolic Energy Pathway Inhibition

The second domain engages Clorsulon, an inhibitor of key enzymes within the anaerobic glycolytic pathway—the liver fluke's primary energy source. By blocking this essential metabolic sequence, Clorsulon rapidly depletes the adult trematode's ATP reserves, causing critical energy starvation and metabolic shutdown. This action is crucial for targeting organisms that rely heavily on glycolysis, leading to the fluke's immobilization and physiological demise.

---

Resulting Mechanistic Complementarity

The strategic combination of a neurotoxic mechanism and a metabolic inhibitory mechanism provides complementary broad-spectrum coverage, where each component targets organisms susceptible to its specific pathway interference. This approach leverages the distinct biologies of nematodes/arthropods and trematodes by hitting two separate, essential molecular targets.

How to use Ivomec F

Ivomec F is a sterile solution containing ivermectin and clorsulon and is indicated for the treatment and control of various internal and external parasites in cattle, including gastrointestinal roundworms, lungworms, adult liver flukes (Fasciola hepatica), and external parasites like sucking lice and mites.

Administration and Dosage

The product should be administered only via subcutaneous injection (under the skin). It must not be given intravenously or intramuscularly. To ensure the correct route of administration, the animal must be appropriately restrained.

Live Weight (kg)	Dose Volume (mL)
50	1
100	2
150	3
200	4
250	5

The recommended dosage is 1 mL per 50 kg (110 lb) of body weight. This delivers 200 mu g of ivermectin and 2 mg of clorsulon per kg of body weight. The injection is typically administered under the loose skin either in front of or behind the shoulder.

For doses exceeding 10 mL, the total volume should be divided and injected into two separate sites to minimize potential discomfort or local tissue reactions. Use a fresh, sterile 16-gauge, 1/2 to 3/4 inch needle, and ensure all equipment is sterile and the injection site is sanitized before use. To prevent potential difficulties due to increased viscosity, the product and equipment may be warmed to about 15°C (59°F) when temperatures are cold. Do not underdose; ensure the dose is based on the animal's current, accurately determined weight.

Ivomec F: Recent Clinical Evidence

Evidence for Use in Gastrointestinal Roundworms and Lungworms

The types of studies used for the Ivermectin component and internal parasites include Controlled Efficacy Studies and specialized Dose-Confirmation Trials. These studies explored the drug’s use in young stock and growing cattle, focusing on outcomes related to systemic or functional imbalance. Researchers monitored measures such as actual parasite counts and Fecal Egg Count Reduction (FECR). Studies describe group patterns where measured changes in these parasite count outcomes were reported in the treatment groups. Research suggests that the documentation of study findings focuses on a select list of species and stages of the parasites, and evidence is limited for other species or for the complete, sustained prevention of reinfection across all common species.

Evidence for Use in Adult Liver Fluke Infection

The evidence base for the Clorsulon component was evaluated in research settings exploring outcomes related to liver flukes (Fasciola hepatica). The research mainly includes Controlled Efficacy Studies and Comparative Efficacy Field Trials, examining temporary physiological imbalance. The primary study outcomes monitored were the count of adult liver flukes and reduction in Liver Fluke Egg Counts. Studies reported patterns where measured adult fluke counts and egg output were monitored in the evaluated groups. The flukicide component was not studied for immature or early immature life stages of the liver fluke, meaning research is limited regarding outcomes observed during these specific phases.

Key Evidence Gaps and Areas of Uncertainty

A synthesis of the research highlights several areas where clarity is needed. The evidence quality varies across studies, particularly for long-term production outcomes where certainty remains low due to environmental variables. Subgroup findings are uncertain, as regulatory data mostly focus on the general target population without extensive subgroup analyses for different breeds or older animal populations.

Common questions about Ivomec F (FAQ)

Q: What is the difference between Ivomec F and plain Ivomec?

A: Official product information indicates that Ivomec F is a dual-active product containing both ivermectin and clorsulon. This differs from plain Ivomec, which contains only ivermectin. The addition of the clorsulon component expands the product's coverage to include adult liver flukes.

Q: Can Ivomec F be used in younger adult populations?

A: Ivomec F is approved for use in cattle. Regulatory restrictions prohibit its use in pre-ruminating calves or calves intended for veal. Studies and official information confirm the product is used in younger stock and growing cattle that are outside these specific exclusions.

Q: Is Ivomec F typically used in older adults?

A: The drug is approved for general use in cattle, which includes older animals like breeding bulls and pregnant beef cows. However, a synthesis of the regulatory evidence notes that specific clinical data for older animal populations may be limited or uncertain.

Q: What is the general frequency of adverse events reported in clinical trials of Ivomec F?

A: The most common reported adverse events are described as low-incidence, temporary discomfort, and soft-tissue swelling at the injection site. Regulatory information warns that severe, sometimes fatal, host-parasite reactions can occur if the drug is administered when certain parasites are present in vital areas.

Q: Do any specific food types or supplements interact with Ivomec F?

A: The veterinary product labeling does not detail specific food interactions for cattle. For the ivermectin component (in human formulations), official sources note that the drug is metabolized by the CYP3A4 enzyme, which can be affected by substances like grapefruit juice.

Q: Are there any specific warning signs or symptoms described in regulatory information for Ivomec F?

A: Common side effects are limited to mild local discomfort and swelling at the injection site. The official label warns of the potential for severe host-parasite reactions if the migrating parasite Hypoderma larvae are destroyed in vital areas, which necessitates careful timing of treatment.

Q: Are the reported side effects for Ivomec F the same for all age groups?

A: Ivomec F is specifically prohibited for use in pre-ruminating calves and veal calves. For eligible cattle populations, evidence summaries indicate that clinical data regarding side effect consistency across different age groups, such as older animals, may be uncertain or lack extensive analysis.

Q: Is Ivomec F metabolized by the body in a unique way?

A: Ivermectin, one of the drug's active ingredients, belongs to the macrocyclic lactone class, which is described as having a 'unique mode of action.' This unique activity involves the selective binding to glutamate-gated chloride channels found only in the nerve and muscle cells of susceptible invertebrates.

Q: How quickly does Ivomec F usually start to have an effect?

A: The exact time for the onset of action is not precisely specified in regulatory documents. However, studies show that a single treatment is proven to control and protect animals from re-infection with certain parasites (such as lungworms) for up to 28 days.

Q: How long does the effect of one dose of Ivomec F last in the body?

A: Regulatory evidence indicates that one dose offers a persistent effect against certain parasites. For some species of lungworms and roundworms, this protection against re-infection is shown to last for up to 28 days after administration.

Q: Is Ivomec F intended to be used for a short time or long-term?

A: Ivomec F is administered as a single-dose injection, designed to provide a persistent therapeutic effect for several weeks (up to 28 days for some parasites). It is intended to be used as part of a professional, planned parasite control program that may require retreatment.

Q: Why is Ivomec F only available with a prescription?

A: The official product information specifies that Ivomec F is a veterinary medicine for use in cattle only. Due to the requirement for a correct subcutaneous injection technique and the potential for serious host-parasite reactions, professional oversight and a prescription are necessary.

Q: Are there certain common over-the-counter medicines that could interact with Ivomec F?

A: The veterinary label does not specifically address common over-the-counter medicines. For the ivermectin component, regulatory sources indicate potential interactions with medicines that inhibit the CYP3A4 enzyme, which includes certain types of antifungals, antivirals, or antibiotics.

Q: Can Ivomec F be taken with basic vitamins or mineral supplements?

A: The official veterinary label does not provide information regarding basic vitamins or mineral supplements. For the ivermectin component, regulatory-cited human information does not report specific vitamin interactions. The use of concurrent supplements should be managed by a veterinary professional.

Q: Does Ivomec F require any routine monitoring or tests during treatment?

A: The regulatory label does not mandate any routine monitoring or tests for the animal immediately following the injection. Regulatory information advises consultation with a veterinarian to establish a planned parasite control program, which includes diagnosis and management.

Q: Is there a maximum length of time for which Ivomec F is typically used?

A: The label does not specify a maximum treatment duration for Ivomec F. It is formulated as a single dose that provides prolonged protection (e.g., up to 28 days for some parasites) and is used as needed within a total parasite control strategy.

Q: Is it necessary to finish the entire course of Ivomec F even if the condition seems better?

A: Ivomec F is administered as a single, weight-based injection. The label contains an explicit warning: 'Do not underdose.' The label emphasizes the importance of correct, complete administration based on the animal's weight to help prevent ineffective treatment.

Q: What does the official drug label say about stopping Ivomec F unexpectedly?

A: Since Ivomec F is administered as a single, complete injection, the label does not provide instructions on stopping an ongoing course. Official guidance focuses on the importance of correct and complete administration of the single dose to achieve the intended efficacy.

Q: What is known about the potential for Ivomec F to interact with herbal products?

A: The veterinary label is silent regarding interactions with herbal products. However, for the ivermectin component, regulatory-cited information notes that certain herbal products, like St. John's Wort, are known to affect the CYP enzymes responsible for the drug's metabolism.

Storage and Disposal of Ivomec F

Storage of Ivomec F (Ivermectin and Clorsulon Injection) must adhere to regulatory specifications to ensure product stability. The medicine must be stored at Controlled Room Temperature, specifically between 68 F – 77 F (20 C – 25 C), and should not exceed 86 F (30 C). Mandatory conditions require protection from light, which is achieved by storing the product in its original carton.

After the bottle is first punctured, the contents must be used within 6 months. If the product is stored at cold temperatures (below 5 C), it may need to be warmed to approximately 15 C before injection to manage viscosity.

As a requirement for child safety, the product must be kept out of the sight and reach of children.

Disposal must follow specific environmental protocols due to the product's active ingredients. Unused medicine and waste containers must not contaminate water and are required to be disposed of by incineration or in an approved landfill in accordance with local regulations.